MBX Biosciences (MBX) announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the ...
Peer-reviewed publication features positive results from multiple ascending dose (MAD) portion of Phase 1 MBX 2109 study in ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
CARMEL, Ind. – MBX Biosciences, Inc. (NASDAQ:MBX) has announced the completion of its Phase 1 trial for MBX 1416, a potential treatment for post-bariatric hypoglycemia (PBH), a condition with no ...
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...